Bridgeway Capital Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
Other funds holding KROS
Bridgeway Capital Management's KROS Position: Q3 2026 in Review
Bridgeway Capital Management increased its Keros Therapeutics (KROS) stake by 2.1% in Q3 2026, buying an estimated $61K and bringing the position to 270,595 shares worth $3.08M. The position accounts for 0.06% of the portfolio, ranked #402.
Bridgeway Capital Management first reported a position in KROS in Q4 2025 and has held it in 4 quarters since. 119 funds tracked by Wall St. Rank hold KROS as of Q3 2026.
- Bridgeway Capital Management held 270,595 shares of Keros Therapeutics worth $3.08M as of Q3 2026.
- Bridgeway Capital Management bought 5,578 Keros Therapeutics shares in Q3 2026, an estimated $61K.
- Keros Therapeutics made up 0.06% of Bridgeway Capital Management's portfolio in Q3 2026, its #402 holding.
- Bridgeway Capital Management first reported a position in Keros Therapeutics in Q4 2025 and has held it in 4 quarters since.
- 119 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.